- Home
- ZURA vs ACRS Comparison
ZURA vs ACRS Comparison
Compare ZURA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- ACRS
- Stock Information
- Founded
- ZURA 2022
- ACRS 2012
- Country
- ZURA United States
- ACRS United States
- Employees
- ZURA N/A
- ACRS N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ZURA Health Care
- ACRS Health Care
- Exchange
- ZURA Nasdaq
- ACRS Nasdaq
- Market Cap
- ZURA 122.8M
- ACRS 132.0M
- IPO Year
- ZURA N/A
- ACRS 2015
- Fundamental
- Price
- ZURA $1.78
- ACRS $2.56
- Analyst Decision
- ZURA Buy
- ACRS Strong Buy
- Analyst Count
- ZURA 6
- ACRS 5
- Target Price
- ZURA $15.80
- ACRS $11.00
- AVG Volume (30 Days)
- ZURA 514.2K
- ACRS 920.8K
- Earning Date
- ZURA 03-12-2025
- ACRS 02-25-2025
- Dividend Yield
- ZURA N/A
- ACRS N/A
- EPS Growth
- ZURA N/A
- ACRS N/A
- EPS
- ZURA N/A
- ACRS N/A
- Revenue
- ZURA N/A
- ACRS $27,079,000.00
- Revenue This Year
- ZURA N/A
- ACRS N/A
- Revenue Next Year
- ZURA N/A
- ACRS N/A
- P/E Ratio
- ZURA N/A
- ACRS N/A
- Revenue Growth
- ZURA N/A
- ACRS 26.35
- 52 Week Low
- ZURA $1.60
- ACRS $0.95
- 52 Week High
- ZURA $6.35
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- ZURA 39.89
- ACRS 46.66
- Support Level
- ZURA $1.71
- ACRS $2.33
- Resistance Level
- ZURA $1.92
- ACRS $2.56
- Average True Range (ATR)
- ZURA 0.14
- ACRS 0.13
- MACD
- ZURA 0.03
- ACRS 0.02
- Stochastic Oscillator
- ZURA 38.54
- ACRS 66.67
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.